Close monitoring of HIV viral load is crucial to prevent LLV among HIV-positive patients on ART, particularly older adults with low CD4+ counts and a history of PI use.
HIV-1 protease inhibitors mimic the protease cleavage site with very tight binding to the protease to block its activity. The current most potent protease inhibitor is darunavir, which reaches levels ...
Scientists, researchers, engineers, industry leaders and innovators gather for UK's must-attend industry event ...
HIV’s Tat protein blocks autophagy in macrophages, letting Mtb thrive. This may explain why HIV patients face higher TB risk even on ART.
The stock-trading website Raging Bull just gave Cocrystal Pharma, a clinical-stage biotech, a big thumbs up for its ...
An international study led by researchers from the Department of Medicine and Life Sciences (MELIS) of Pompeu Fabra ...
Researchers have designed a screening system to identify extremely selective peptides with therapeutic potential that ...
An international study led by researchers from the Department of Medicine and Life Sciences (MELIS) of Pompeu Fabra University and Stanford ...
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback